Top Companies in Cell and Gene Therapy in Europe

We’re thrilled to present the Top Companies in Cell and Gene Therapy in Europe, a prestigious honor recognizing the industry’s game-changers. These exceptional businesses were nominated by our subscribers based on impeccable reputation and the trust these companies have garnered from our valued subscribers. After an intense selection process—led by C-level executives, industry pioneers, and our expert editorial team—only the best have made the cut. These companies have been selected as recipients of the award, celebrating their leadership, and innovation.

Top Companies in Cell and Gene Therapy in Europe

EVis Bioscience

Read full profile →

EVis Bioscience is redefining RNA delivery with a hybrid system that fuses biological precision with engineering control. By stabilising extracellular vesicles for high-efficiency RNA loading, the company enables more targeted, scalable ... read full profile

FamiCord

Read full profile →

FamiCord is Europe’s largest stem cell banking group, trusted by families for nearly three decades. It offers complete services from collection at birth to therapeutic use, with 15 accredited laboratories worldwide. Through advanced ... read full profile

Cellex

Cellex is a company with years of experience in autologous and allogeneic cell therapy. It partners with top pharma companies, biotech firms, and academic institutions supporting clinical trials and post approval productions. Its approved CAR-T therapies are produced in our facilities, ensuring GMP compliant operations. Its expertise includes cell collection, supply chain management, and consulting on GMP processes and regulations.

Cellistic

Cellistic is a biotechnology company that specializes in manufacturing advanced cell therapies using induced pluripotent stem cell (iPSC) technology. It uses proprietary platforms Pulse™ and Echo™ to turn iPSCs into edited, banked cell lines and then scale up production into therapeutic products. It has a certified facility and advanced gene editing tools, Cellistic supports biotech partners in developing off-the-shelf, allogeneic immune cell therapies at clinical scale.

OXB Oxford Biomedica

OXB Oxford Biomedica is a global contract development and manufacturing organization focused on cell and gene therapy and is one of its original pioneers. It has years of expertise producing viral vectors to enable clients’ biologic therapies. OXB offers end-to-end services, from vector design to clinical and commercial scale manufacturing. It is already collaborating with world’s most innovative pharmaceutical and biotechnology companies towards a shared mission to make cell and gene therapy a universally accessible clinical option.

ProtaGene

ProtaGene is a world's leading CRO partner for the biopharmaceutical and cell and gene therapy industries. It provides the most advanced, integrated, and complete protein and gene analytic capabilities and packages for biologic therapeutics as well as cell and gene therapy platforms. Its combined protein and gene based analytical platforms make it the leading analytic service provider across the cell and gene therapy development spaces.

RoslinCT

RoslinCT is a global company specializing in advanced cell and gene therapy development. It produces clinical grade human pluripotent stem cells and offers process development, gene editing, and GMP manufacturing. It supported the first approved CRISPR-edited therapy, and runs 22 purpose built GMP suites for autologous and allogeneic therapies.

Cell and Gene Therapy Companies News

Educational and Awareness Aspects of Cell and Gene Therapy

Tuesday, December 24, 2024

Europe's strong scientific foundation, supportive regulatory environment, and increased investment position it as a leader in CGT, driving innovation, improving patient outcomes, and fostering economic growth. FREMONT CA: Cell and gene therapy (CGT) represents a groundbreaking advancement in medicine with the potential to transform the treatment of numerous diseases. However, widespread adoption necessitates a robust foundation of education and awareness among healthcare professionals and the general public. Educating healthcare professionals (HCPs) is vital for CGT's safe and effective implementation. This education equip

European Microbiome Research for Diagnosing and Treating Diseases

Wednesday, May 01, 2024

The European microbiome, influenced by fermented foods, antibiotics, and urbanisation, is transforming healthcare through advanced sequencing techniques, allowing for microbiome-based diagnostics and therapeutics. FREMONT, CA: The human body comprises a complex ecosystem hosting trillions of microbes, including bacteria, fungi, archaea, and viruses, collectively called the microbiome. These microscopic inhabitants play pivotal roles in health and disease, impacting various aspects such as digestion, immunity, and mental well-being. Exploring the European microbiome is a rapidly evolving field with significant potential to transform healthca

Cell and Gene Therapy Companies Info

What Do Top Cell and Gene Therapy Companies in Europe Do?

Top Cell and Gene Therapy Companies in Europe develop advanced treatments that use living cells, genetic material or engineered biological processes to address serious diseases. Their work may include autologous and allogeneic cell therapies, viral and non-viral gene delivery, manufacturing platforms, clinical development and regulatory strategy. In a Top editorial context, the focus is not only on scientific promise but also on execution, patient relevance, quality systems and the ability to move complex therapies toward reliable clinical and commercial use.

Why Does Cell and Gene Therapy Matter Now in Europe?

Cell and Gene Therapy Companies in Europe matter because healthcare systems, clinicians and patients are looking for more durable approaches to difficult diseases, including cancers, rare disorders and inherited conditions. Europe has a strong advanced therapy medicinal products framework, respected research institutions and growing specialist manufacturing capacity. Demand is shaped by clinical need, regulatory maturity, reimbursement complexity and the need to scale therapies safely. The category is important because it sits at the intersection of science, medicine, production quality and patient access.

How Are Leading Cell and Gene Therapy Companies Typically Evaluated?

Editorial evaluation of cell and gene therapy companies usually considers scientific credibility, development pipeline quality, manufacturing depth, regulatory progress, clinical evidence and leadership expertise. A strong company should show more than early-stage innovation; it should demonstrate disciplined trial design, scalable production thinking, safety monitoring and a clear understanding of European market access expectations. Top Cell and Gene Therapy Companies in Europe are also assessed by how well they manage complexity across research, clinical translation, quality control, partnerships and long-term therapy delivery.

What Value Do Cell and Gene Therapy Innovators Create for Patients and Healthcare Systems?

Cell and gene therapy innovators create value by pursuing treatments that may address disease mechanisms rather than only managing symptoms. For patients and families, that can mean new options where standard care is limited. For healthcare systems, the value depends on evidence, durability, safety, affordability and practical delivery models. In Europe, where national reimbursement pathways differ, companies must show clinical benefit while also supporting responsible access. Strong cell and gene therapy companies balance innovation with evidence quality, manufacturing reliability and patient-centered treatment design.

How Do Innovation and Manufacturing Expertise Shape the Category?

Innovation in cell and gene therapy is closely tied to process control, analytics, automation, vector design, cell engineering and supply chain resilience. A promising therapy can face delays if production is inconsistent or difficult to scale. Leading gene therapy developers and cell therapy providers invest in quality systems, specialized facilities, digital monitoring and improved manufacturing workflows. Expertise matters because these therapies often involve sensitive biological materials, short timelines and strict release criteria. The strongest companies treat manufacturing as a strategic capability, not a late-stage technical function.

What Should Stakeholders Prioritize When Comparing Cell and Gene Therapy Companies?

Stakeholders comparing Top Cell and Gene Therapy Companies in Europe should look for a balanced mix of science, clinical progress, manufacturing readiness and regulatory understanding. Investors may prioritize pipeline strength, platform flexibility and partnership strategy, while clinicians and healthcare leaders may focus on safety, evidence quality and patient access. Policymakers and payers may examine durability, cost justification and delivery feasibility. The most credible companies are those that combine advanced biology with disciplined execution, transparent development practices and a realistic path from innovation to patient benefit.

Specials

Top Companies in Cell and Gene Therapy in Europe

Top Companies in Cell and Gene Therapy in Europe

Educational and Awareness Aspects of Cell and Gene Therapy

European Microbiome Research for Diagnosing and Treating Diseases

Cell and Gene Therapy Companies Info